Cancer Family
Hematopoietic and Lymphoid Cell Neoplasm
CI-CAN-00000023Explore in graph →
HematologicNon-malignant4,231 active trials98 approved drugs1,009 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000023Explore in graph →
Clinical trials
18,680 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05596981 | The Gut Microbiome in FLT3-ITD+ AML Undergoing Allo-HSCT With Or Without Sorafenib Maintenance After Allo-HSCT | unknown | — | 60 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Oct 27, 2022 | clinicaltrials |
| NCT05497310 | Effectiveness and Safety of Therapy Based on Attenuated ATO Plus Low-Dose ATRA in Patients With APL | unknown | Phase 1 / Phase 2 | 15 | Hospital Universitario Dr. Jose E. GonzalezOTHER | 1 | Oct 26, 2022 |
| clinicaltrials |
| NCT05135858 | Dose Dense Re-challenge of High Dose Methotrexate With Glucarpidase for Relapsed Primary Central Nervous System Lymphoma(METHOGLU) | unknown | Phase 1 | 18 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Oct 25, 2022 | clinicaltrials |
| NCT05592470 | commd7 Gene Expression in ALL | unknown | — | 102 | Assiut UniversityOTHER | 0 | Oct 24, 2022 | clinicaltrials |
| NCT05413356 | Ruxolitinib for Newly Diagnosed Bronchiolitis Obliterans Syndrome | unknown | Phase 2 | 50 | First Affiliated Hospital of Zhejiang UniversityOTHER | 1 | Oct 19, 2022 | clinicaltrials |
| NCT05587088 | Evaluation of the Safety and Efficacy of Esperanza Extract (PA001)(PA001) | unknown | Phase 1 / Phase 2 | 82 | Hospital Universitario San IgnacioOTHER | 1 | Oct 19, 2022 | clinicaltrials |
| NCT05577611 | An Open, Single Center, Randomized Controlled Clinical Study of UCB (Cord Blood) in the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML) | unknown | Phase 1 | 57 | Zhongnan HospitalOTHER | 1 | Oct 13, 2022 | clinicaltrials |
| NCT05578378 | Cladribine Combined With G-CSF and Cytarabine as a Salvage Treatment in R/R ALL | unknown | Phase 2 / Phase 3 | 32 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Oct 13, 2022 | clinicaltrials |
| NCT05578625 | ctDNA Methylation Sequencing for Myeloma | unknown | — | 66 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Oct 13, 2022 | clinicaltrials |
| NCT03318770 | Post-Frontline Sequential Treatment of Adult Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia | unknown | — | 60 | Gruppo Italiano Malattie EMatologiche dell'AdultoOTHER | 1 | Oct 12, 2022 | clinicaltrials |
| NCT03825367 | Nivolumab in Combination With 5-azacytidine in Childhood Relapsed/Refractory AML | unknown | Phase 1 / Phase 2 | 13 | Therapeutic Advances in Childhood Leukemia ConsortiumOTHER | 1 | Oct 12, 2022 | clinicaltrials |
| NCT04118868 | Pembrolizumab Administered Via the Sofusa® DoseConnect™ in Patients With Relapsed/Refractory Cutaneous T-cell Lymphoma. | unknown | Phase 1 | 10 | Sorrento Therapeutics, Inc.INDUSTRY | 1 | Oct 12, 2022 | clinicaltrials |
| NCT04438044 | A Study to Evaluate ICP-022 in Patients With R/R PCNSL and SCNSL | unknown | Phase 2 | 61 | Beijing InnoCare Pharma Tech Co., Ltd.INDUSTRY | 1 | Oct 12, 2022 | clinicaltrials |
| NCT05575973 | Mitoxantrone Hydrochloride Liposome Combined With Rituximab and Lenalidomide (M+R2) in Patients With Relapsed and Refractory Diffuse Large B-Cell Lymphoma | unknown | Phase 2 | 55 | Jianfeng ZhouOTHER | 1 | Oct 12, 2022 | clinicaltrials |
| NCT03697707 | Efficacy and Safety of Immunotherapy With Allogeneic Dendritic Cells, DCP-001, in Patients With Acute Myeloid Leukaemia(ADVANCE-II) | unknown | Phase 2 | 20 | MendusINDUSTRY | 5 | Oct 10, 2022 | clinicaltrials |
| NCT05569057 | A Phase I Trial of SIM1811-03 in Subjects With Advanced Solid Tumors and Cutaneous T-cell Lymphoma | unknown | Phase 1 | 100 | Jiangsu Simcere Pharmaceutical Co., Ltd.INDUSTRY | 1 | Oct 7, 2022 | clinicaltrials |
| NCT03169296 | Clinical and Genomic Registry of MDS in Asia | unknown | — | 2,600 | The University of Hong KongOTHER | 1 | Oct 4, 2022 | clinicaltrials |
| NCT03624270 | Oral Arsenic Trioxide for Newly Diagnosed Acute Promyelocytic Leukaemia | unknown | Phase 2 | 60 | The University of Hong KongOTHER | 1 | Oct 4, 2022 | clinicaltrials |
| NCT04226768 | Enhanced Palliative Care in MDS and AML | unknown | N/A | 90 | The University of Hong KongOTHER | 1 | Oct 4, 2022 | clinicaltrials |
| NCT04251754 | The Acute Promyelocytic Leukaemia Asian Consortium (APL-AC) Project | unknown | — | 1,000 | The University of Hong KongOTHER | 1 | Oct 4, 2022 | clinicaltrials |
| NCT04689815 | Oral Arsenic Trioxide for NPM1-mutated AML | unknown | Phase 2 | 50 | The University of Hong KongOTHER | 1 | Oct 4, 2022 | clinicaltrials |
| NCT05566535 | Changes in QoL and Symptoms in Patients With Polycythemia Vera Receiving Ruxo in a Routine Clinical Practice(QoL-PV-R) | unknown | — | 32 | Multinational Center for Quality of Life Research, RussiaOTHER | 0 | Oct 4, 2022 | clinicaltrials |
| NCT05561049 | Efficacy and Safety of Daratumumab in Combination With Bortezomib, Thalidomide, and Dexamethasone Regimens in Newly Diagnosed Multiple Myeloma | unknown | — | 120 | The First Affiliated Hospital of Soochow UniversityOTHER | 0 | Sep 30, 2022 | clinicaltrials |
| NCT04033627 | TCDαβ/CD45RA Haploidentical Transplantation in Children With Leukemia | unknown | N/A | 30 | Shanghai Children's Medical CenterOTHER | 1 | Sep 29, 2022 | clinicaltrials |
| NCT05367856 | Efficacy and Safety of Chidamide Combined With BEAM Pretreatment Regimen in Autologous Transplantation for T-cell Lymphoma | unknown | Phase 2 | 23 | Ruijin HospitalOTHER | 1 | Sep 29, 2022 | clinicaltrials |
| NCT05559450 | Blinatumomab as a Bridge to Allo-HSCT in HR BCP-ALL | unknown | Phase 2 | 80 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Sep 29, 2022 | clinicaltrials |
| NCT05557903 | Phase Ⅰ Clinical Study of Anti-CD52 Monoclonal Antibody in NHL and T-PLL | unknown | Phase 1 | 71 | Lanzhou Institute of Biological Products Co., LtdINDUSTRY | 1 | Sep 28, 2022 | clinicaltrials |
| NCT04684472 | Modified CD19 CAR-T in Patients With Relapsed or Refractory CD19+ B-cell Malignancies | unknown | Phase 1 | 18 | Liqun ZouOTHER | 1 | Sep 26, 2022 | clinicaltrials |
| NCT04352556 | COVID19-hematological Malignancies: the Italian Hematology Alliance | unknown | — | 250 | Ospedale di Circolo - Fondazione MacchiOTHER | 1 | Sep 23, 2022 | clinicaltrials |
| NCT05549284 | Orelabrutinib,Rituximab and Methotrexate in Newly-diagnosed Primary Central Nervous System Lymphoma(PCNSL)(RMO) | unknown | Phase 2 | 36 | Affiliated Hospital to Academy of Military Medical SciencesOTHER | 1 | Sep 22, 2022 | clinicaltrials |
| NCT05549973 | Anlotinib Hydrochloride Capsule Monotherapy and Combination Therapy Relapsed and Refractory Multiple Myeloma | unknown | Phase 1 | 32 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Sep 22, 2022 | clinicaltrials |
| NCT05548686 | Benefits of Adapted Physical Activity for Chronic Osteoarticular Pain in Patients With Multiple Myeloma(ALGOMYELOMOV) | unknown | N/A | 15 | University Hospital, CaenOTHER | 0 | Sep 21, 2022 | clinicaltrials |
| NCT03280160 | Protocol GELLC-7: Ibrutinib Followed by Ibrutinib Consolidation in Combination With Ofatumumab | unknown | Phase 2 | 84 | PETHEMA FoundationOTHER | 1 | Sep 16, 2022 | clinicaltrials |
| NCT05543070 | Low-dose Radiotherapy in iNHL | unknown | Phase 2 | 73 | Chinese Academy of Medical SciencesOTHER | 1 | Sep 16, 2022 | clinicaltrials |
| NCT05543161 | "Peripheral Blood Dipeptidylpeptidase IV (CD26) Positive Leukemic Stem Cells in Chronic Myeloid Leukemia as a Diagnostic Marker" | unknown | — | 50 | Sohag UniversityOTHER | 1 | Sep 16, 2022 | clinicaltrials |
| NCT03891355 | Carfilzomib + Lenalidomide and Dexamethasone for BTK Inhibitors Relapsed-refractory or Intolerant MCL(FIL_KLIMT) | unknown | Phase 2 | 16 | Fondazione Italiana Linfomi - ETSOTHER | 1 | Sep 15, 2022 | clinicaltrials |
| NCT05536700 | Using Mass Spectrometry (EasyM) Detecting Minimal Residual Disease (MRD) in Multiple Myeloma | unknown | — | 67 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Sep 13, 2022 | clinicaltrials |
| NCT04277845 | Randomized Phase II Study in Elderly Patients With Newly Diagnosed Multiple Myeloma(KMM1910) | unknown | Phase 2 | 49 | Samsung Medical CenterOTHER | 1 | Sep 9, 2022 | clinicaltrials |
| NCT04248595 | Study of Azacitidine Combined With Homoharringtonie Based Regimens in AML | unknown | Phase 2 | 100 | Ge ZhengOTHER | 1 | Sep 8, 2022 | clinicaltrials |
| NCT04688853 | A Study to Investigate the Safety and Efficacy of TEG002 in Relapsed/Refractory Multiple Myeloma Patients | unknown | Phase 1 | 26 | Gadeta B.V.INDUSTRY | 1 | Sep 8, 2022 | clinicaltrials |
| NCT05532761 | Multidimensional Assessment of Quality of Life, Social and Professional Life and Care Utilization in Patients With Diffuse Large Cell B-cell Lymphoma Treated With CAR-T Cells(QUALITOP CAR-T) | unknown | — | 30 | Hospices Civils de LyonOTHER | 1 | Sep 8, 2022 | clinicaltrials |
| NCT03336073 | Carfilzomib, Cyclophosphamide, Dexamethasone in Multiple Myeloma | unknown | Phase 2 | 199 | PETHEMA FoundationOTHER | 1 | Sep 7, 2022 | clinicaltrials |
| NCT05528887 | Study of CAR-T Cell Therapy in the Treatment of Relapsed/Refractory Hematological Malignancies | unknown | Phase 1 | 10 | The Affiliated People's Hospital of Ningbo UniversityOTHER_GOV | 1 | Sep 6, 2022 | clinicaltrials |
| NCT05466175 | A Study of Olverembatinib in the Treatment of Ph+ ALL | unknown | Phase 2 | 55 | Chen SuningOTHER | 1 | Sep 1, 2022 | clinicaltrials |
| NCT05189782 | Mechanism of Resistance to GNC-038 in Relapsed and Refractory Diffuse Large B-cell Lymphoma | unknown | — | 15 | Ruijin HospitalOTHER | 1 | Aug 31, 2022 | clinicaltrials |
| NCT03552003 | Study for Elderly (≥ 65 Years) Patients With Classical Hodgkin Lymphoma Undergoing CGA at Diagnosis | unknown | — | 400 | Fondazione Italiana Linfomi - ETSOTHER | 1 | Aug 26, 2022 | clinicaltrials |
| NCT05518318 | GLS-010 Monotherapy Versus Chemotherapy in Patients With Relapsed or Refractory Classical Hodgkin's Lymphoma (R/R cHL) | unknown | Phase 3 | 60 | Guangzhou Gloria Biosciences Co., Ltd.INDUSTRY | 0 | Aug 26, 2022 | clinicaltrials |
| NCT05513131 | Clinical Study Protocol of Venetoclax Combined With Azacitidine and Harringtonine in the Treatment of sAML | unknown | Phase 2 | 30 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Aug 24, 2022 | clinicaltrials |
| NCT05512104 | Clinical Characters and Outcome of Acute Myeloid Leukemia Patients on Correlation to CD200 and CD56 Expression | unknown | — | 51 | Assiut UniversityOTHER | 0 | Aug 23, 2022 | clinicaltrials |
Data updated 23 days agoSource updated Oct 27, 2022source: clinicaltrials